Section Arrow
Quote
PHAT.NASDAQ
- Phathom Pharmaceuticals
Quotes are at least 15-min delayed:2025/03/13 18:15 EDT
Last
 4.22
-0.78 (-15.60%)
Day High 
5.05 
Prev. Close
5 
1-M High
6.98 
Volume 
1.42M 
Bid
4.24
Ask
4.37
Day Low
4.185 
Open
4.99 
1-M Low
4.325 
Market Cap 
348.18M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.33 
20-SMA 5.48 
50-SMA 6.24 
52-W High 19.71 
52-W Low 4.325 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.29/-2.32
Enterprise Value
549.59M
Balance Sheet
Book Value Per Share
-3.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
55.25M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc0.0334-0.0234-41.20%0PE
CRVOCervoMed5.79-0.38-6.16%4.66PE
HEPAHepion Pharmaceuticals0.0378-0.011-22.54%-- 
IPAImmunoPrecise Antibodies Ltd0.405+0.0417+11.48%-- 
ONCOOnconetix Inc0.1298-0.0412-24.09%-- 
Quotes are at least 15-min delayed：2025/03/13 18:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.